Amgen (AMGN) Proxy filing summary

Executive summary

• Achieved 10% year-over-year revenue and sales growth in 2025, with 18 products reaching record sales and 14 exceeding $1 billion in sales.

• Advanced R&D with five FDA approvals and significant progress in obesity, oncology, rare disease, and inflammation pipelines.

• Invested $7 billion in R&D, $2 billion in strategic capital projects, and expanded U.S. manufacturing with $1.55 billion in new investments.

• Reduced debt by $6 billion and returned $5 billion to shareholders via dividends.

• Maintained disciplined capital allocation and continued philanthropic and educational outreach.

Voting matters and shareholder proposals

• Board recommends voting FOR all director nominees, executive compensation, and auditor ratification; AGAINST proposal for an independent Board chair.

• Annual meeting scheduled for May 19, 2026, to be held virtually.

• Board opposes independent chair proposal, citing strong performance and robust independent oversight mechanisms.

Board of directors and corporate governance

• Board comprises 12 nominees, 11 of whom are independent; 8 new directors appointed since 2016.

• Board members bring diverse expertise in science, healthcare, finance, and technology.

• Lead independent director has significant responsibilities and is elected annually.

• Board refreshment and director commitment levels are reviewed annually.

• Key committees are fully independent and include Audit, Compensation, Corporate Responsibility, and Governance.